

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Lartruvo (olaratumab)

CG-DRUG-102

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Lartruvo (olaratumab)

### APPROVAL CRITERIA

Requests for Lartruvo (olaratumab) may be approved when the following criteria are met:

- I. Individual has a histologically confirmed diagnosis of late stage soft tissue sarcoma (locally advanced or metastatic) not previously treated with an anthracycline; **AND**
- II. Radiotherapy or surgery is not a curative treatment option; **AND**
- III. Individual's current Eastern Cooperative Oncology Group (ECOG) performance status is 0-2; **AND**
- IV. If the individual is less than 18 years of age, Lartruvo is not used as first-line chemotherapy; **AND**
- V. Lartruvo is being used in combination with doxorubicin and, after at least 8 cycles with doxorubicin or earlier discontinuation of doxorubicin due to toxicity, and then if so chosen, continuing Lartruvo as monotherapy in the absence of unacceptable toxicities until disease progression.

Lartruvo (olaratumab) may **not** be approved when the medically necessary criteria are not met and for all other indications.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

1. Lartruvo [Product Information], Indianapolis, IN. Eli Lilly and Co., February 2017. Available at: <http://pi.lilly.com/us/lartruvo-uspi.pdf>. Accessed on March 26, 2018.
2. National Comprehensive Cancer Network® NCCN Clinical Practice Guidelines in Oncology™. For additional information visit the NCCN website: <http://www.nccn.org>. Accessed on March 26, 2018.
  - a. Soft Tissue Sarcoma (V.1.2018). Revised October 21, 2017.
3. National Institute of Health. A randomized, double-blind, placebo-controlled, phase 3 trial of doxorubicin plus olaratumab versus doxorubicin plus placebo in patients with advanced or metastatic soft tissue sarcoma. Clinical trials.gov Identifier: NCT02451943. Last updated on August 28, 2017. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT02451943?term=NCT02451943&rank=1>. Accessed on March 26, 2018.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.